A single arm, multicenter, open-label, 52-week, the omnibus extension study to evaluate the safety and efficacy of telbivudine in the fifth year of treatment in chinese patients with compensated chronic hepatitis B and are HBV [hepatitis B virus] DNA PCR [polymerase chain reaction] negative at the end of year 4 treatment.

Trial Profile

A single arm, multicenter, open-label, 52-week, the omnibus extension study to evaluate the safety and efficacy of telbivudine in the fifth year of treatment in chinese patients with compensated chronic hepatitis B and are HBV [hepatitis B virus] DNA PCR [polymerase chain reaction] negative at the end of year 4 treatment.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Telbivudine (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 13 Apr 2009 Planned end date changed from 1 Sep 2009 to 1 Jul 2011 as reported by ClinicalTrials.gov.
    • 18 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top